Next Phase Newsletter

A venture capital firm based in the Netherlands is raising a new fund, with a target of over EUR 100 million. The firm invests all over Europe, and the new fund will have the capacity to invest in the US as well. The firm invests up to EUR 12 million, and may make larger investments from the new fund. The firm generally leads financing rounds.

The firm focuses on therapeutic modalities and platforms, including small molecules, antibodies, cell therapies, and screening platforms including genetic screening. The fund is indication agnostic and typically invests at an early stage.

The firm is a very active investor and typically leads rounds, but can also be a follow-on investor. The firm also sometimes takes part in company generation and new spin-outs from universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A venture capital firm based in Silicon Valley works closely with major incubators globally, through which they are able to identify high-potential, disruptive technologies. The firm is actively investing in early-stage companies and generally participates in Series A to B financing rounds. The initial size of investment depends largely on the company’s stage of development. The firm seeks investments globally.

The firm will consider opportunities in therapeutics, diagnostics, and digital health/healthcare IT. The firm is most interested in data-centric and enterprise technologies. The firm is agnostic to subsector and indication, but the firm will generally avoid medical device companies and early-stage therapeutics companies (i.e. those that take longer than 18 months to commercialize). That said, the firm may consider derisked assets or those that have an accelerated pathway to commercialization. Within healthcare IT technologies, the firm would like to see revenue-generating companies with good consumer traction.

The firm invests in both publicly traded and privately-owned companies. The firm is an active investor and will directly engage in the growth of their portfolio companies through a number of value-ons, including brand building, international expansion, talent recruiting, operation and technical guidance, etc. The firm need not have a fully established management team prior to investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email: mandates@lifesciencenation.com.

A private life science investment firm has a presence in U.K, Canada and multiple locations in U.S. The firm looks to make investments into privately held companies and while the firm can be flexible in terms of allocation size, most investments fall in the $0.5 – 3 million range. The firm is open to investing in companies located around the globe.

The firm is currently looking for therapeutics companies across all indication areas with particular attention to metabolic diseases (including type II diabetes), immune-oncology, aging, and infectious diseases. The firm is interested in pre-clinical stage companies that have a lead asset established as well as companies in early clinical trials. The firm is open to all molecule types that meet this criteria. The firm is generally not interested in next generation cytotoxic chemotherapies, therapies for Alzheimer’s Disease, or therapies for cardiovascular indications.

The firm is a hands-on investor who contribute substantially to the operation of their portfolio companies, often supplementing management with a network of drug developers and specialists in regulatory affairs, clinical affairs, manufacturing, and other subspecialties.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A specialized US venture capital firm under a holding group company focuses on finance, conducting business with its Chinese sister company as one group. The firm has headquarters in China and an additional virtual office in the U.S. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds. The average size of investment is ~ $5M. The firm has invested in 17 US & Canada companies since 2016. The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies. The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA. The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team. The firm generally takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital and private equity firm invests in breakthrough industrial technologies and, within the life sciences, is looking to invest in companies developing R&D and manufacturing tools and services. The firm is interested in companies that have at least some data through a pilot or a pharma partner to validate their technology. The firm invests primarily in North America-based companies, but will consider international companies that have significant operations in the US.

The firm invests in tools and services for R&D and manufacturing within the life sciences. This can include diagnostics platforms, AI/ML based drug discovery platforms, analytics or manufacturing tools. The firm invests primarily in technologies that do not require FDA approval, and looks for companies with some data validation of their technology with an external partner.

The firm prefers to lead and take a board seat when investing, but will occasionally co-invest as well. The firm will also consider follow-on investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in East Coast USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm based in headquartered in Japan has a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, but may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine.  The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area, and invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor.  For early stage opportunities, the firm prefers that the company has a clinical trial plan in place.  While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.